Graduates of the CUNY Graduate Center's Ph.D. program in Computer Science become masters of the computer science discipline and obtain in-depth knowledge of a specialized area. CUNY Graduate Center Ph ...

The BSN Pathway is built on a traditional four-year undergraduate curriculum that provides a foundational education that includes both academic and professional nursing courses essential for clinical ...

Will Kenton is an expert on the economy and investing laws and regulations. He previously held senior editorial roles at Investopedia and Kapitall Wire and holds a MA in Economics from The New School ...

Our summer interns gain an insider’s view of the member-country-focused mandate and critical international work of the IMF. You will build professional networks while you apply your research and ...

Purdue University's online Master of Science in Communication is designed for professionals ready to excel in the dynamic field of communication. Tailor your degree with six concentration options and ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

The White House Internship Program is a public service leadership program that provides a unique opportunity to gain valuable professional experience and build leadership skills. Learn more about ...

Wondering if Recursion Pharmaceuticals at around $4.83 is a beaten down bargain or a value trap? This breakdown walks through what the current market price is really implying. The stock has bounced ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...